Alebund Pharmaceuticals (Jiangsu) Limited

礼邦医药(江苏)股份有限公司

09637.HK

Clinical-stage biopharmaceutical company developing therapies for renal indications, including AP301, a phosphate binder for hyperphosphatemia in dialysis patients, in Phase III trials in China and the US; per CIC, it has the broadest renal indication coverage globally.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Distribution model
• Reliance on platforms, partners or licences
• Single product, business line or region
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-IFRS measures and adjustments
• Related-party transactions and balances
• Material share-based payments
• Chapter 18A biotech